Decreased p-tau levels by SLCP treatment may be due to inhibition of tau kinases, such as GSK-3β [35, 36], which were increased by Aβ42 treatment and which have been observed in the AD brain [37–39]. Here, MAPT is linked to Alzheimer disease.